Literature DB >> 8257148

Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations.

J S Hostetler1, J Heykants, K V Clemons, R Woestenborghs, L H Hanson, D A Stevens.   

Abstract

Pharmacologic studies of itraconazole (IZ), a triazole antifungal, indicated unexplained differences between bioassay and chromatographic determinations and large variations in steady-state blood concentrations. We show that concentrations of a hydroxylated metabolite, hydroxyitraconazole (HIZ), are approximately twofold higher than IZ over a range of concentrations. Though HIZ and IZ appear equipotent against selected pathogens, HIZ is two to three times more active against a commonly used bioassay fungus but minimally affects IZ activity. Hence, HIZ probably contributes importantly to the therapeutic activity attributed to IZ and contributes approximately four to six times the activity of IZ in bioassays, explaining discrepancies observed between assay methods.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257148      PMCID: PMC192254          DOI: 10.1128/AAC.37.10.2224

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents.

Authors:  D W Denning; L H Hanson; A M Perlman; D A Stevens
Journal:  Diagn Microbiol Infect Dis       Date:  1992-01       Impact factor: 2.803

2.  Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography.

Authors:  R Woestenborghs; W Lorreyne; J Heykants
Journal:  J Chromatogr       Date:  1987-01-23

3.  Pharmacokinetics of itraconazole following oral administration to normal volunteers.

Authors:  T C Hardin; J R Graybill; R Fetchick; R Woestenborghs; M G Rinaldi; J G Kuhn
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 4.  The clinical pharmacokinetics of itraconazole: an overview.

Authors:  J Heykants; A Van Peer; V Van de Velde; P Van Rooy; W Meuldermans; K Lavrijsen; R Woestenborghs; J Van Cutsem; G Cauwenbergh
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

5.  Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion.

Authors:  L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

6.  Treatment of mycoses with itraconazole.

Authors:  R M Tucker; P L Williams; E G Arathoon; D A Stevens
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

7.  Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole.

Authors:  D W Warnock; A Turner; J Burke
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

8.  Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations.

Authors:  R M Tucker; D W Denning; L H Hanson; M G Rinaldi; J R Graybill; P K Sharkey; D Pappagianis; D A Stevens
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

  8 in total
  19 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.

Authors:  Timothy H Waterhouse; Stefanie Redmann; Stephen B Duffull; John A Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

3.  Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum.

Authors:  GholamAli Khoschsorur; Franz Fruehwirth; Sieglinde Zelzer
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Systemic availability of itraconazole in lung transplantation.

Authors:  T F Patterson; J Peters; S M Levine; A Anzueto; C L Bryan; E Y Sako; O L Miller; J H Calhoon; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Simultaneous quantitation of five triazole anti-fungal agents by paper spray-mass spectrometry.

Authors:  Christine L Skaggs; Greta J Ren; El Taher M Elgierari; Lillian R Sturmer; Run Z Shi; Nicholas E Manicke; Lindsey M Kirkpatrick
Journal:  Clin Chem Lab Med       Date:  2020-04-28       Impact factor: 3.694

6.  Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors:  S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.

Authors:  James Kim; Jean Y Tang; Ruoyu Gong; Jynho Kim; John J Lee; Karl V Clemons; Curtis R Chong; Kris S Chang; Mark Fereshteh; Dale Gardner; Tannishtha Reya; Jun O Liu; Ervin H Epstein; David A Stevens; Philip A Beachy
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

Review 8.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

9.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 10.  Optimisation of itraconazole therapy using target drug concentrations.

Authors:  J M Poirier; G Cheymol
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.